EP1157126A4 - Method for cloning signal transduction intermediates - Google Patents

Method for cloning signal transduction intermediates

Info

Publication number
EP1157126A4
EP1157126A4 EP00911997A EP00911997A EP1157126A4 EP 1157126 A4 EP1157126 A4 EP 1157126A4 EP 00911997 A EP00911997 A EP 00911997A EP 00911997 A EP00911997 A EP 00911997A EP 1157126 A4 EP1157126 A4 EP 1157126A4
Authority
EP
European Patent Office
Prior art keywords
signal transduction
transduction intermediates
cloning
cloning signal
intermediates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00911997A
Other languages
German (de)
French (fr)
Other versions
EP1157126A1 (en
Inventor
Brian Seed
Adrian Ting
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1157126A1 publication Critical patent/EP1157126A1/en
Publication of EP1157126A4 publication Critical patent/EP1157126A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
EP00911997A 1999-02-24 2000-02-24 Method for cloning signal transduction intermediates Withdrawn EP1157126A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12148599P 1999-02-24 1999-02-24
US121485P 1999-02-24
PCT/US2000/004925 WO2000050633A1 (en) 1999-02-24 2000-02-24 Method for cloning signal transduction intermediates

Publications (2)

Publication Number Publication Date
EP1157126A1 EP1157126A1 (en) 2001-11-28
EP1157126A4 true EP1157126A4 (en) 2005-03-02

Family

ID=22397020

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00911997A Withdrawn EP1157126A4 (en) 1999-02-24 2000-02-24 Method for cloning signal transduction intermediates

Country Status (4)

Country Link
EP (1) EP1157126A4 (en)
JP (1) JP2002541779A (en)
AU (1) AU3380200A (en)
WO (1) WO2000050633A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA006108B1 (en) 1999-01-25 2005-08-25 Байоджен, Инк. Method of stimulation and inhibition of b-cells, production of immunoglobulins and correction of disorders associated with baff-ligand in an animal
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
BR0013391A (en) 1999-08-17 2002-07-09 Biogen Inc Use of the baff receptor (bcma) as an immunoregulatory agent
UA74798C2 (en) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Method for treating cancer in mammals using polypeptide interfering with interaction between april and its receptors
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7371388B1 (en) 2000-05-04 2008-05-13 Human Genome Sciences, Inc. Treatment of Sjogren's syndrome by administration of TR18 polypeptides
UA83458C2 (en) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf)
DE10300222A1 (en) * 2003-01-03 2004-07-15 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Use of active substances for the prophylaxis and / or therapy of viral diseases
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
BRPI0414714A (en) * 2003-09-24 2006-11-21 Pasteur Institut purified polynucleotide, vector, host cell, polypeptide fusion construct, methods of inhibiting the nf-capab signaling pathway, disrupting nemo oligomerization, and identifying polypeptides that modulate nemo oligomerization, and use of a effective amount of a composition
CA2629306A1 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
US20100305002A1 (en) * 2009-04-27 2010-12-02 Roswell Park Cancer Institute Reagents and Methods for Producing Bioactive Secreted Peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519336A2 (en) * 1991-06-18 1992-12-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Chimeric gene comprising a promoter-regulater and a gene coding for an indicator protein
WO1996017927A2 (en) * 1994-12-05 1996-06-13 Karo Bio Ab Reporter cell line
US5702897A (en) * 1994-04-13 1997-12-30 The Burnham Institute Interaction of proteins involved in a cell death pathway
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519336A2 (en) * 1991-06-18 1992-12-23 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Chimeric gene comprising a promoter-regulater and a gene coding for an indicator protein
US5702897A (en) * 1994-04-13 1997-12-30 The Burnham Institute Interaction of proteins involved in a cell death pathway
WO1996017927A2 (en) * 1994-12-05 1996-06-13 Karo Bio Ab Reporter cell line
US5783435A (en) * 1996-08-06 1998-07-21 Lamparski; Henry G. Prostate cancer drug screenings

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HUANG YU-LUN ET AL: "Bcl-2 blocks apoptotic signal of transforming growth factor-beta in human hepatoma cells", JOURNAL OF BIOMEDICAL SCIENCE, vol. 5, no. 3, May 1998 (1998-05-01), pages 185 - 191, XP002295489, ISSN: 1021-7770 *
LAÂBI Y ET AL: "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 11, 1992, pages 3987 - 3904, XP002156771, ISSN: 0261-4189 *
MADRY C ET AL: "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily", INTERNATIONAL IMMUNOLOGY 1998 UNITED KINGDOM, vol. 10, no. 11, 1998, pages 1693 - 1702, XP000982102, ISSN: 0953-8178 *
See also references of WO0050633A1 *
WILLIAMS T M ET AL: "ADVANTAGES OF FIREFLY LUCIFERASE AS A REPORTER GENE: APPLICATION TO THE INTERLEUKIN-2 GENE PROMOTER", ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, NEW YORK, NY, US, vol. 176, no. 1, 1989, pages 28 - 32, XP000601607, ISSN: 0003-2697 *

Also Published As

Publication number Publication date
JP2002541779A (en) 2002-12-10
WO2000050633A1 (en) 2000-08-31
WO2000050633A9 (en) 2001-10-11
EP1157126A1 (en) 2001-11-28
AU3380200A (en) 2000-09-14

Similar Documents

Publication Publication Date Title
EP1109555A4 (en) Novel angiogenesis inhibitors
EP1097147A4 (en) Novel angiogenesis inhibitors
PL350818A1 (en) Improved attachment method for piezoelectric elements
GB0023072D0 (en) Apparatus for receiving ranging signals
GB9920644D0 (en) Novel method
GB9925559D0 (en) Novel method
EP1190082A4 (en) Method of inducing angiogenesis by micro-organs
EP1157126A4 (en) Method for cloning signal transduction intermediates
IL145677A0 (en) Pcr-based cloning method
EP1083695A4 (en) Apparatus for eliminating interference signal
GB0025448D0 (en) Method for optimally determining sensor positions for acoustic pyrometry
HUP0102348A3 (en) Novel method for preparing synthesis intermediates
GB2390669B (en) Signal apparatus
GB2356694B (en) Signal apparatus
PL365058A1 (en) Processes and intermediates for preparing benzyl substituted epoxides
GB9909749D0 (en) Purification method
IL147004A0 (en) Chimeric oca-b transcription factors
GB2348519B (en) Method for compensating signal
AU2002215721A1 (en) Method of cloning animals
AU3263101A (en) Expression cloning method
GB9930682D0 (en) Novel intermediates for chiral scaffolds
GB9801007D0 (en) Process for synthesizing carbapenem intermediates
GB9806023D0 (en) Process for synthesizing carbapenem intermediates
GB9904158D0 (en) Novel method
HU9903736D0 (en) Process an intermediates for preparing hicotinamide derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010924

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RBV Designated contracting states (corrected)

Designated state(s): CH DE FR GB LI

RIC1 Information provided on ipc code assigned before grant

Ipc: 7G 01N 33/554 B

Ipc: 7A 61K 38/00 B

Ipc: 7C 12N 7/00 B

Ipc: 7C 12Q 1/00 A

Ipc: 7C 12N 5/02 B

Ipc: 7C 12Q 1/66 B

Ipc: 7C 07H 21/00 B

Ipc: 7C 12N 5/00 B

Ipc: 7C 07H 21/04 B

Ipc: 7C 07H 21/02 B

Ipc: 7C 12Q 1/70 B

Ipc: 7C 12Q 1/68 B

A4 Supplementary search report drawn up and despatched

Effective date: 20050112

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050802